MX2015008685A - Tratamiento de artritis psoriasica usando apremilast. - Google Patents

Tratamiento de artritis psoriasica usando apremilast.

Info

Publication number
MX2015008685A
MX2015008685A MX2015008685A MX2015008685A MX2015008685A MX 2015008685 A MX2015008685 A MX 2015008685A MX 2015008685 A MX2015008685 A MX 2015008685A MX 2015008685 A MX2015008685 A MX 2015008685A MX 2015008685 A MX2015008685 A MX 2015008685A
Authority
MX
Mexico
Prior art keywords
apremilast
psoriatic arthritis
treatment
methods
managing
Prior art date
Application number
MX2015008685A
Other languages
English (en)
Inventor
Robert Day
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015008685(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2015008685A publication Critical patent/MX2015008685A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Se describen métodos de tratamiento, manejo o prevención de artritis psoriásica. Los métodos específicos abarcan la administración de apremilast, solo o en combinación con un segundo agente activo.
MX2015008685A 2013-03-14 2014-03-13 Tratamiento de artritis psoriasica usando apremilast. MX2015008685A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782880P 2013-03-14 2013-03-14
PCT/US2014/025171 WO2014151180A1 (en) 2013-03-14 2014-03-13 Treatment of psoriatic arthritis using apremilast

Publications (1)

Publication Number Publication Date
MX2015008685A true MX2015008685A (es) 2015-10-05

Family

ID=50549444

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008685A MX2015008685A (es) 2013-03-14 2014-03-13 Tratamiento de artritis psoriasica usando apremilast.

Country Status (10)

Country Link
US (1) US9872854B2 (es)
KR (1) KR20150126618A (es)
CN (1) CN105050624A (es)
AU (1) AU2014235273A1 (es)
BR (1) BR112015020584A2 (es)
HK (1) HK1215671A1 (es)
IL (1) IL239499A0 (es)
MX (1) MX2015008685A (es)
NZ (1) NZ628320A (es)
WO (1) WO2014151180A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2420498T3 (en) 2006-09-26 2017-08-14 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
CA3037184C (en) 2011-03-11 2021-04-06 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
JP2015531776A (ja) 2012-09-04 2015-11-05 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
EP3188745A1 (en) * 2014-08-15 2017-07-12 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
CN105588886B (zh) * 2014-11-18 2020-01-31 重庆医药工业研究院有限责任公司 一种采用液相色谱法测定阿普斯特及其制剂中杂质的方法
CN104458961A (zh) * 2014-12-11 2015-03-25 南京艾德凯腾生物医药有限责任公司 阿普斯特有关物质检测方法
US10287248B2 (en) 2015-03-19 2019-05-14 Cipla Limited Process for the preparation of apremilast
CN106727344A (zh) * 2015-11-19 2017-05-31 常州爱诺新睿医药技术有限公司 一种无定型阿普斯特的固体分散体及其制备方法
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105935350B (zh) * 2015-12-18 2018-11-16 重庆两江药物研发中心有限公司 一种阿普斯特缓释植入剂及其制备方法
KR20180097623A (ko) * 2015-12-24 2018-08-31 지앙수 헨그루이 메디슨 컴퍼니 리미티드 아프레밀라스트 서방형 제제
CN108181401B (zh) * 2018-01-26 2020-07-31 华侨大学 一种阿普斯特片有效成分的含量测定方法
CN109568302B (zh) * 2018-11-01 2021-07-16 郑州大学第一附属医院 一种治疗晚期肝癌的药物复合物及其应用
US11357775B2 (en) 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
CA3138473A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
EP4132570A1 (en) * 2020-04-08 2023-02-15 Nostrum Pharmaceuticals, LLC Compositions and methods using interferon for treating viral respiratory infections
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer
WO2023121670A1 (en) * 2021-12-23 2023-06-29 Amgen Inc. Oral suspension of apremilast

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
JP2008523102A (ja) 2004-12-13 2008-07-03 セルジーン・コーポレーション Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用
CN101932571B (zh) * 2008-01-18 2014-04-23 奥克萨根有限公司 具有crth2拮抗活性的化合物
MX2010010334A (es) 2008-03-24 2010-10-08 Celgene Corp Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
MX2011002589A (es) 2008-09-10 2011-04-07 Celgene Corp Procesos para la preparacion de compuestos de aminosulfona.
EP2501382A1 (en) * 2009-11-19 2012-09-26 Celgene Corporation Apremilast for the treatment of sarcoidosis

Also Published As

Publication number Publication date
KR20150126618A (ko) 2015-11-12
NZ628320A (en) 2017-04-28
WO2014151180A1 (en) 2014-09-25
BR112015020584A2 (pt) 2017-07-18
IL239499A0 (en) 2015-08-31
AU2014235273A2 (en) 2015-07-23
CN105050624A (zh) 2015-11-11
US20150174100A2 (en) 2015-06-25
HK1215671A1 (zh) 2016-09-09
US9872854B2 (en) 2018-01-23
AU2014235273A1 (en) 2015-07-09
US20140301980A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
MX2015008685A (es) Tratamiento de artritis psoriasica usando apremilast.
PL3554631T3 (pl) Leczenie pacjentów polami ttfields ze zoptymalizowanymi pozycjami elektrod z wykorzystaniem odkształcalnych matryc
TW201613887A (en) Antiproliferative compounds and methods of use thereof
EP3054954A4 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
SG10201806787VA (en) Modulators of complement factor b
EP2876119A4 (en) GEL, LEAKAGE SEALING METHOD THEREFOR AND DRILLING TOTE PUMPING PROCESS THEREWITH
EP2967633A4 (en) DEVICES, SYSTEMS AND METHOD FOR SKIN TREATMENT
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
MX2015016319A (es) Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas.
MX2016000696A (es) Compuestos terapeuticos activos y sus usos.
EP2944323A4 (en) MEANS FOR THE TREATMENT OF TUMORS, USE AND METHOD THEREFOR
MX2015010077A (es) Terapia de combinacion para el tratamiento de neumonia nosocomial.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2016014384A (es) Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
MX2017000141A (es) Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
PH12020550185A1 (en) Semaglutide in medical therapy
MX2018011222A (es) Ambrisentan para uso en el tratamiento de insuficiencia renal aguda.
HK1199930A1 (zh) 相互作用的調節劑及其在治療癌症中的用途
MX2015012505A (es) Métodos mejorados para tratamiento de grano con ozono.
GB2556531A (en) Medical devices, systems, and methods utilizing antithrombin-heparin compositions
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation